Crinetics Pharmaceuticals (NASDAQ:CRNX) PT Lowered to $33.00

Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price objective decreased by HC Wainwright from $35.00 to $33.00 in a research note issued to investors on Wednesday, MarketBeat reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Crinetics Pharmaceuticals’ Q3 2023 earnings at ($0.83) EPS, Q4 2023 […]

Related Keywords

Marc Wilson ,Piper Sandler ,Coelho Rogerio Vivaldi ,Analyst Recommendations For Crinetics Pharmaceuticals ,Securities Exchange Commission ,Hsbc Holdings ,Crinetics Pharmaceuticals Price Performance ,News Ratings For Crinetics Pharmaceuticals Daily ,Blackrock Inc ,Crinetics Pharmaceuticals ,Manufacturers Life Insurance Company ,Campbell Co Investment Adviser ,Crinetics Pharmaceuticals Inc ,Institutional Trading Of Crinetics Pharmaceuticals ,Free Report ,Director Coelho Rogerio Vivaldi ,Exchange Commission ,Get Free Report ,Crinetics Pharmaceuticals Daily ,Nasdaq Crnx ,Crnx ,Medical ,Lower Price Target ,Hc Wainwright ,